• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Pharmaceutical Medicine

    Pharmaceutical Medicine

    JournalISSN 1178-2595eISSN 1179-1993中科院 医学 4区

    年发文量

    研究主题

    论文(1129)

    排序
    1Perceptions of Australian Medical Affairs and Cross-Functional Participants on the Role of Medical Affairs in Quality Use of Medicines (QUM)
    Matthew Britland,Anita Heywood, Lois Meyer, David Grolman,Orin Chisholm

    Medical Affairs (MA) is increasingly recognised as a strategic and scientific function within the pharmaceutical industry, with responsibilities spanning evidence generation, stakeholder engagement and support for the Quality Use of Medicines (QUM). However, particularly in the Australian context, there is limited empirical evidence examining how MA’s contribution to QUM is understood, articulated and evaluated within pharmaceutical organisations. This study aimed to examine and compare the perceptions of Australian MA and cross-functional (CF) participants regarding MA’s contribution, professional competencies, organisational value and alignment with QUM and business objectives. Semi-structured qualitative interviews were conducted with 21 participants (11 Medical Affairs [MA] and 10 cross-functional [CF] participants) working across MA, regulatory, market access, commercial and sales functions within Australian pharmaceutical companies. Participants were purposively sampled to ensure diversity in role, seniority and organisational context. Interviews were guided by literature on the evolving role of MA and professional capability development. Overall, 35 potential participants were directly invited, of whom 21 participated. Thematic saturation was considered to have been reached at approximately interview 16. Data were analysed using thematic analysis. Among the 11 MA and 10 CF participants, MA participants described their contribution to QUM through scientific education, evidence interpretation, real-world evidence generation and healthcare professional (HCP) and patient engagement. CF participants acknowledged these contributions but highlighted challenges in quantifying MA’s impact using conventional performance metrics. Both groups supported structured competency frameworks, greater recognition of MA’s ethical and scientific stewardship and a shift towards outcome-oriented measures of value. MA is increasingly perceived by participants as an important contributor to QUM through scientific engagement and insight generation. Realising this potential will require improved cross-functional understanding, adaptable competency frameworks and performance metrics aligned with QUM outcomes rather than traditional commercial outputs.

    2026
    引用
    AI阅读
    加入学术空间
    2Regulatory Pathways and Pivotal Trial Characteristics of Medicines Designated under the European Medicines Agency’s Priority Medicines Scheme Approved Between 2018 and 2024
    Vanessa A. Prieto, María Luján Iavecchia, Esther Cucurull, Juan F. Pacheco Páramo

    The European Medicines Agency (EMA) PRIority MEdicines (PRIME) scheme supports the development of medicines addressing unmet medical needs through early scientific and regulatory guidance. The aim of this study was to describe the regulatory pathways and pivotal trial characteristics of PRIME-designated medicines that received a positive Committee for Medicinal Products for Human Use (CHMP) opinion between 2018–2024. In this retrospective descriptive analysis, public EMA documents were reviewed. Extracted variables included regulatory characteristics (orphan drugs designation, advanced therapy medicinal products, new active substances, accelerated assessment, conditional marketing authorisation, exceptional circumstances and withdrawals), procedural timelines and pivotal trial features (phase, randomisation, blinding, comparator, number of arms, sample size and objectives). The analysis was conducted in two parts. In the first part, medicine was the unit of analysis to describe characteristics and regulatory pathways. In the second part, the unit of analysis was the medicine-indication pair defined as a unique combination of a medicine and an authorised indication and used to describe the main studies on which the CHMP based its positive opinion. Different indications for the same medicine were analysed separately when supported by distinct evidence packages, whereas indications supported by a common evidence package were analysed jointly to avoid double counting. Categorical variables were expressed as frequencies and proportions. Time intervals were calculated in calendar days and summarised as medians with interquartile range (IQR). Thirty-six PRIME-designated medicines received a positive CHMP opinion between 2018 and 2024. Oncology was the most frequent therapeutic area (12/36, 33.3

    2026
    引用
    AI阅读
    加入学术空间
    3Eight Hallmarks for Governing Artificial Intelligence in Medical Affairs: A Structured Pathway for Responsible AI Adoption
    Georgios Bakalos, Thomas Loenneker, Stefanie Srock, Ash Das-Gupta, Arthur Canon, Thomas Buechele, Jorge Martinalbo, Nicolas Lindegger, Artem Zharkov,Chrysoula Doxani,Elias Zintzaras

    Medical Affairs (MA) is the pharmaceutical medicine discipline responsible for medically governed scientific exchange, post-approval evidence generation, and stakeholder engagement. As MA adopts artificial intelligence (AI), governance must keep pace. We propose that AI use be directed by MA accountability and named human medical judgement. The European Union (EU) AI Act’s transparency provisions generally apply from August 2026. Its high-risk requirements apply from 2 December 2027 for Annex III systems and 2 August 2028 for systems classified through Annex I. In this narrative review, we critically examine the emerging evidence base and current regulatory guidance to propose eight hallmarks characterising AI-enabled MA. Four are foundational governance capabilities: scientific and ethical integrity, evidence generation at scale, advanced scientific communications, and global alignment and regulatory adaptation. Four are emerging applications requiring validation: AI-empowered strategic leadership, AI-enhanced stakeholder engagement, field medical excellence, and digital innovation and agentic AI systems. Named human accountability underpins all eight hallmarks. We provide pharmaceutical leaders with author-proposed implementation tools including a maturity assessment model, a mapping of common MA AI use cases to EU AI Act obligations, a medical-legal-regulatory workflow for AI-generated content, and equity-by-design metrics. The framework proposes a governance-first, structured pathway for responsible AI adoption in MA that is designed to preserve scientific integrity.

    2026
    引用
    AI阅读
    加入学术空间
    4The Role of Clinical Pharmacists in Translating Regulatory Acceptance of Biosimilars into Routine Clinical Practice.
    Montserrat Viñas-Bastart, Marcelo Correas Sanahuja, Antonio J. Braza,Pilar Modamio, Josep Maria Guiu-Segura

    Advances in analytical characterisation, functional assays, pharmacokinetic evaluation and manufacturing science have enabled regulatory agencies to increasingly rely on the totality of evidence, reducing the need for comparative clinical efficacy trials in scientifically justified circumstances. Consequently, the principal challenge surrounding biosimilars has shifted from demonstrating biosimilarity to ensuring their effective implementation in routine clinical practice. Despite this strong scientific consensus, variability in clinical uptake persists across healthcare systems, limited by professional uncertainty, patient concerns, organisational barriers and inadequate communication. Clinical pharmacists are uniquely positioned to bridge this gap between regulatory science and clinical implementation. This article discusses concrete strategies through which pharmacists translate regulatory confidence into clinical confidence, including interpretation of comparability evidence for prescribers, structured patient counselling to mitigate the nocebo effect and support shared decision-making, coordination of switching and traceability programmes, multidisciplinary education, and pharmacovigilance and real-world evidence generation. Their contributions across hospital, community and ambulatory care settings are explored, together with their strategic role in Pharmacy and Therapeutics Committees, procurement processes and health policy implementation. Beyond facilitating biosimilar adoption, pharmacists contribute to healthcare sustainability by promoting value-based medicine, resilient procurement strategies, responsible resource allocation and environmentally conscious pharmaceutical practices. Future opportunities, including digital pharmacovigilance, artificial intelligence and personalised implementation strategies, are also discussed. Clinical pharmacists should therefore be regarded not only as medicines experts but also as knowledge translators capable of transforming regulatory guidance into patient-centred clinical practice and sustainable healthcare delivery.

    2026
    引用
    AI阅读
    加入学术空间
    5Ataxia Therapeutics: A Comprehensive Overview of the Clinical Development Pipeline
    Marisa Cappella,Nicoletta Locuratolo, Marco Salvatore,Agata Polizzi,Elena Carbone, Federica Perrone,Guido Bellomo,Nicola Vanacore,Eleonora Lacorte,Paola Piscopo

    Ataxias are a heterogeneous group of rare neurological disorders characterized by progressive impairment of motor coordination and balance, caused by a broad range of genetic, immune-mediated, and degenerative mechanisms. Despite significant advances in molecular diagnostics and disease characterization, effective disease-targeted treatments remain limited, with omaveloxolone currently representing the only approved therapy for Friedreich’s ataxia. In this review, we provide a comprehensive and up-to-date overview of the clinical drug development pipeline for ataxias, based on a systematic analysis of international clinical trial registries up to April 2026. One hundred and fifty-four interventional pharmacological trials investigating 66 therapeutic agents across phases 1–3 were identified. The majority of ongoing clinical efforts focus on symptomatic and supportive therapies, which together constitute more than half of the pipeline and include the most developmentally advanced programs. Neuroprotective therapies represent a substantial portion of trials but have shown mixed efficacy to date. In contrast, disease-targeted approaches, including gene therapies, antisense oligonucleotides, cell-based therapies, and protein replacement strategies, account for a smaller share of the pipeline and remain largely confined to early-phase development. More than half of investigational agents are repurposed compounds, reflecting a pragmatic strategy to accelerate therapeutic progress in rare disorders. Overall, the ataxia therapeutic landscape is expanding but remains fragmented, underscoring the need for improved patient stratification, validated biomarkers, harmonized registries, and international collaboration to enable the successful translation of emerging therapies into clinical practice.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1129 篇论文

    高被引作者

    作者引用发文
    Frank Wells116325
    Jürgen Kübler7302
    Reinhard Fescharek7271
    Ulrich Elsasser7271
    Monika Frank7271
    Mary Ellen Kitler3637
    Julie M Donohue3391
    Takeshi Suda1771
    Zhang Guisheng1771
    Kenya Kamimura1771

    高产作者

    作者引用发文
    Robert N Smith3819
    Francis Crawley5415
    Philip Ambery5014
    Adrian Kilcoyne5014
    Daniel O'Connor1612
    Sue Pochon3211
    Criscuolo Domenico1911
    Walker Stuart10110
    Daniel O’Connor488
    Mamoru Narukawa407

    相关期刊

    Drug Target Insights
    Therapeutic advances in drug safety
    Therapeutic Innovation & Regulatory Science
    Journal of market access & health policy
    Pharmacogenomics Journal
    Therapie
    Farmacia Hospitalaria
    Clinical Pharmacology & Therapeutics
    Journal of managed care & specialty pharmacy
    CTS-Clinical and Translational Science